Evidence map›Paper›PMID 30008325›Full record

ArticleStem cell reports2018

Translational Control of Sox9 RNA by mTORC1 Contributes to Skeletogenesis.

Takashi Iezaki, Tetsuhiro Horie, Kazuya Fukasawa, Makoto Kitabatake, Yuka Nakamura, Gyujin Park, Yuki Onishi, Kakeru Ozaki, Takashi Kanayama, Manami Hiraiwa and 6 more

Open access · goldAbstract read
In one paragraph

Article in Stem cell reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 28 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 4 institutions in 1 country.

Takashi IezakiLaboratory of Molecular Pharmacology, Division of Pharmaceutical Sciences, Kanazawa University Graduate School, Kakuma-machi, Kanazawa, Ishikawa 920-1192, Japan; Venture Business Laboratory, Organization of Frontier Science and Innovation, Kanazawa University, Kanazawa, Ishikawa 920-1192, Japan.
Tetsuhiro HorieLaboratory of Molecular Pharmacology, Division of Pharmaceutical Sciences, Kanazawa University Graduate School, Kakuma-machi, Kanazawa, Ishikawa 920-1192, Japan.
Kazuya FukasawaLaboratory of Molecular Pharmacology, Division of Pharmaceutical Sciences, Kanazawa University Graduate School, Kakuma-machi, Kanazawa, Ishikawa 920-1192, Japan.
Makoto KitabatakeInstitute for Virus Research, Kyoto University, Kyoto 606-8507, Japan.
Yuka NakamuraMedical Research Institute, Kanazawa Medical University, Kahoku, Ishikawa 920-0293, Japan.
Gyujin ParkLaboratory of Molecular Pharmacology, Division of Pharmaceutical Sciences, Kanazawa University Graduate School, Kakuma-machi, Kanazawa, Ishikawa 920-1192, Japan.
Yuki OnishiLaboratory of Molecular Pharmacology, Division of Pharmaceutical Sciences, Kanazawa University Graduate School, Kakuma-machi, Kanazawa, Ishikawa 920-1192, Japan.
Kakeru OzakiLaboratory of Molecular Pharmacology, Division of Pharmaceutical Sciences, Kanazawa University Graduate School, Kakuma-machi, Kanazawa, Ishikawa 920-1192, Japan.
Takashi KanayamaLaboratory of Molecular Pharmacology, Division of Pharmaceutical Sciences, Kanazawa University Graduate School, Kakuma-machi, Kanazawa, Ishikawa 920-1192, Japan.
Manami HiraiwaLaboratory of Molecular Pharmacology, Division of Pharmaceutical Sciences, Kanazawa University Graduate School, Kakuma-machi, Kanazawa, Ishikawa 920-1192, Japan.
Yuka KitaguchiLaboratory of Molecular Pharmacology, Division of Pharmaceutical Sciences, Kanazawa University Graduate School, Kakuma-machi, Kanazawa, Ishikawa 920-1192, Japan.
Katsuyuki KanedaLaboratory of Molecular Pharmacology, Division of Pharmaceutical Sciences, Kanazawa University Graduate School, Kakuma-machi, Kanazawa, Ishikawa 920-1192, Japan.
Takayuki ManabeDepartment of Neuroanatomy and Neuropharmacology, Faculty of Nursing, Chukyogakuin University, Mizunami, Gifu 509-6192, Japan.
Yasuhito IshigakiMedical Research Institute, Kanazawa Medical University, Kahoku, Ishikawa 920-0293, Japan.
Mutsuhito OhnoInstitute for Virus Research, Kyoto University, Kyoto 606-8507, Japan.
Eiichi HinoiLaboratory of Molecular Pharmacology, Division of Pharmaceutical Sciences, Kanazawa University Graduate School, Kakuma-machi, Kanazawa, Ishikawa 920-1192, Japan. Electronic address: hinoi@p.kanazawa-u.ac.jp.
Kanazawa University · JPKanazawa Medical University · JPKyoto University · JPChukyo Gakuin University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The mechanistic/mammalian target of rapamycin complex 1 (mTORC1) regulates cellular function in various cell types. Although the role of mTORC1 in skeletogenesis has been investigated previously, here we show a critical role of mTORC1/4E-BPs/SOX9 axis in regulating skeletogenesis through its expression in undifferentiated mesenchymal cells. Inactivation of Raptor, a component of mTORC1, in limb buds before mesenchymal condensations resulted in a marked loss of both cartilage and bone. Mechanistically, we demonstrated that mTORC1 selectively controls the RNA translation of Sox9, which harbors a 5' terminal oligopyrimidine tract motif, via inhibition of the 4E-BPs. Indeed, introduction of Sox9 or a knockdown of 4E-BP1/2 in undifferentiated mesenchymal cells markedly rescued the deficiency of the condensation observed in Raptor-deficient mice. Furthermore, introduction of the Sox9 transgene rescued phenotypes of deficient skeletal growth in Raptor-deficient mice. These findings highlight a critical role of mTORC1 in mammalian skeletogenesis, at least in part, through translational control of Sox9 RNA.

Indexed as

Protein BiosynthesisAnimalsCell DifferentiationGene ExpressionMechanistic Target of Rapamycin Complex 1MiceMice, TransgenicOsteogenesisPhenotypeSkeletonSOX9 Transcription FactorMechanistic Target of Rapamycin Complex 1Sox9 protein, mouseSOX9 Transcription FactormTORC1Sox9translationundifferentiated mesenchymal cells

Identifiers

PMID30008325
PMCPMC6117477
OpenAlexW2810740673

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.